We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00721331
First Posted: July 24, 2008
Last Update Posted: September 26, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Zalicus
  Purpose
This will be a phase I, single center, randomized, vehicle-controlled, blinded study comparing two dosage strengths of CRx-197 cream, nortriptyline, an active comparator (0.1% mometasone) and placebo (the active ingredient free vehicle cream of CRx-197)in healthy volunteers.

Condition Intervention Phase
Atopic Dermatitis Drug: nortriptyline HCl + loratadine Drug: nortriptyline HCl Drug: mometasone furoate Drug: Active ingredient free vehicle cream of CRx-197 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I, Single-Center, Randomized, Vehicle-Controlled Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Zalicus:

Primary Outcome Measures:
  • Safety and tolerability of CRx-197 as assessed by treatment emergent adverse events, physical exams, vital signs, concomitant medications/procedures and subject assessment of pruritus. [ Time Frame: 2 months ]

Secondary Outcome Measures:
  • Difference in change from baseline in psoriatic infiltrate measured by ultrasound between CRx-197, nortriptyline, active comparator as well as vehicle of CRx-197 and untreated test field(s) [ Time Frame: Days 8, 15, 22, 29 and 43 ]
  • Difference in change from baseline in erythema measured by chronometry between CRx-197, nortriptyline, active comparator, vehicle of CRx-197, untreated test field(s) and normal skin [ Time Frame: Days 8, 15, 22, 29 and 43 ]
  • Modified PASI between CRx-197, nortriptyline, active comparator, vehicle of CRx-197, untreated test field(s) [ Time Frame: Baseline, and Days 8, 15, 22, 29 and 43 ]

Estimated Enrollment: 20
Study Start Date: July 2008
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CRx-197 high dose (0.1% nortriptyline HCl + 0.3% loratadine) Drug: nortriptyline HCl + loratadine
Topical
Experimental: CRx-197 low dose (0.1% nortriptyline HCl + 0.1% loratadine) Drug: nortriptyline HCl + loratadine
Topical
Experimental: 0.1% nortriptyline HCl Drug: nortriptyline HCl
Topical
Active Comparator: 0.1% mometasone furoate Drug: mometasone furoate
Topical
Placebo Comparator: Active ingredient free vehicle cream of CRx-197 Drug: Active ingredient free vehicle cream of CRx-197
Topical

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject must voluntarily sign and date the written Informed Consent prior to any study specific procedures
  • Subject must be 18 to 60 years of age
  • Subject must have healthy skin on which reddening can be easily recognized in the area where they will place the test fields
  • Subject must be free from a condition/disease that the investigator feels interferes with the interpretation of the study results.
  • Females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a highly effective medically accepted contraceptive regimen. A highly effective method of birth control is defined as those which result in a lower failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised partner.

Exclusion Criteria:

  • Suntan, hyper- or hypo-pigmentation, or tattoos in the area where they will place the test fields
  • Dark skinned persons whose skin color prevents ready assessment of skin reactions
  • Cardiac disease, including recent myocardial infarction, any degree of heart block or other cardiac arrhythmias and valvular heart disease
  • Mania
  • Narrow angle glaucoma
  • Hyperthyroidism by medical history, TSH less than LLN, or subject receiving any thyroid medication
  • Severe liver disease - ALT laboratory value that exceeds 1.5x ULN
  • Inflammatory dermatoses (e.g., atopic dermatoses/eczema, psoriasis)
  • Any skin condition involving the test fields including but not limited to bacterial, viral, or fungal skin infections, acne, rosacea
  • Active varicella, tuberculosis, syphilis or post-vaccine reactions
  • Autoimmune disease (e.g., lupus erythematosis)
  • Known allergic reactions or hypersensitivity to any of the components of the study treatments
  • Allergy to adhesives on the patches used for occlusion in the study
  • UV therapy or significant UV exposure in the four weeks before treatment application
  • History of malignancy (except for treated or excised basal cell carcinoma)
  • Surgery within the previous 3 months (except for minor cosmetic or dental procedures)
  • History of drug or alcohol abuse (as defined by the Investigator)
  • Symptoms of a clinically significant illness in the four weeks before treatment application that may influence the outcome of the study
  • Positive for HIV antibody
  • Systemic treatments in the four weeks prior to treatment application that may interact with any of the study drugs, such as: Glucocorticoids, MAO inhibitors, anti-depressants, anti-seizure medications, anti-psychotics and anti-histamines
  • Subjects who require medications that inhibit the CYP450 2D6 pathway such as:Quinidine, Cimetidine, Type 1 anti-arrhythmic, Phenothiazines, Selective serotonin reuptake inhibitors, Reserpine, other anticholinergic drugs, and sympathomimetic drugs
  • Treatment with any investigational agent within one month before treatment application for this trial
  • Female subject who is pregnant , lactating, or with a positive pregnancy test
  • Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule
  • Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment
  • Subject is institutionalized because of legal or regulatory order
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00721331


Locations
Germany
PROINNOVERA GmbH
Muenster, Germany
Sponsors and Collaborators
Zalicus
Investigators
Principal Investigator: Jutta Harten, MD Proinnovera GmbH
  More Information

Responsible Party: James Keane, Sr. Clinical Project Manager, CombinatoRx, Inc.
ClinicalTrials.gov Identifier: NCT00721331     History of Changes
Other Study ID Numbers: CRx-197-001
EudraCT # 2008-000611-15
First Submitted: July 21, 2008
First Posted: July 24, 2008
Last Update Posted: September 26, 2008
Last Verified: September 2008

Keywords provided by Zalicus:
CombinatoRx
Atopic
Dermatitis
Topical
CRx-197
Normal Healthy Volunteers

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Mometasone Furoate
Loratadine
Nortriptyline
Anti-Inflammatory Agents
Dermatologic Agents
Anti-Allergic Agents
Antipruritics
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators